Our Commitment

Alivora Therapeutics is committed to delivering

We invite you to learn more about our science, clinical trials, and patient support programs. Together, we are redefining the future of medicine—rooted in nature and proven by science.

Alivora Therapeutics: Committed to Making a Difference.

We are doing this primarily through our advanced research into the science of natural botanicals and also by providing relevant information to those in the medical profession.

Our research is ongoing into the use of natural botanicals to treat pain and neurological conditions like Multiple Sclerosis and Huntington’s disease.

The last ten years has been interesting and exciting as Alivora therapeutics continues to reach several milestones. We are certain our pharmaceutical medicine will be approved by the FDA and will be available to you the patient in the United States. Our operations are run by some of the most respected and well known scientists, researchers and doctors from around the world. Every day we are breaking new ground with or research and clinical trials. We are undoubtedly setting the framework for an industry that will impact humanity in a lasting and profound way. We know that having serious pain and or a life-threatening disease is extremely challenging. With this in mind, we urge that you take your doctor’s advice but do your own research so that you are empowered to make choices that are right for you and your loved ones. In the meantime, here is some information that we hope will help you along your journey of healing.

Alivora’s FOCUS

Huntington’s Disease

Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical and mental abilities during their prime working years and has no cure. HD is known as the quintessential family disease because every child of a parent with HD has a 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and some at-risk of inheriting the disease.

Symptoms usually appear between the ages of 30 to 50, and worsen over a 10 to 25 year period. Ultimately, the weakened individual succumbs to pneumonia, heart failure or other complications. Everyone has the gene that causes HD, but only those that inherit the expansion of the gene will develop HD and perhaps pass it on to each of their children. Every person who inherits the expanded HD gene will eventually develop the disease. Over time, HD affects the individual’s ability to reason, walk and speak.

Symptoms Include:

Multiple Sclerosis

Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).

In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.

Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected. Some people with severe MS may lose the ability to walk independently or at all, while others may experience long periods of remission without any new symptoms. There’s no cure for multiple sclerosis. However, treatments can help speed recovery from attacks, modify the course of the disease and manage symptoms. For Healthcare professionals.

Alivora Therapeutics is a bio-pharmaceutical company that has developed a final dose form medication from plant extracts. Our ultimate goal is to obtain a Food and Drug Adminstration (FDA) approval for use in US clinical trials. Alivora to date has developed a lipophilic compound for symptomatic treatment of Pain,Multiple Sclerosis(MS), Huntington’s Disease and several other neurological conditions. To date, the company has initiated the FDA IND approval processes for the MS and Huntington’s Disease conditions.

Alivora Therapeutics has a long history of researching cannabinidiol formulations and is well versed in its proven stability, safety and efficacy. We are committed to making a difference in patients’ lives with the power of genomics and information technology.

Providing support for persons in the healthcare profession is important to us and in this regard, Alivora Therapeutics has written a dossier for multi jurisdictional approval for its products.

In addition, we are developing specific development information for physicians so they can better understand the pain staking GMP development procedures Alivora Therapeutics has taken to provide patient safety. Alivora Therapeutics aims to align with the finest and most knowledgeable doctors and nurses in the world and we are grateful for these alliances.

Alivora Therapeutics is on a mission to discover, develop, manufacture and commercialize medicines for the under-served patient populations. We promise to do all we can to equip healthcare professionals with the information and research necessary to recommend that your patients will use our products to alleviate the pain and suffering of those in their care. Alivora Therapeutics-a pioneer in the science of medical cannabis.

Alivora Therapeutics., along with its global partners , is dedicated to advancing the sciences involving patient use of natural botanicals.

According to the American Medical Association and the American Academy of Family Practice, current methods to assess the nation’s largest and most expensive medical conditions are subjective and ineffective.The Alivora Therapeutics family has a better way, utilizing predictive analysis of plant and human genetics and other patient factors.It is our mission to provide patients better information for better health while treating with natural botanicals.

Alivora Therapeutics Accomplishments

To maintain the market leadership in development FDA approved

Cannabinoid medicines and transform the lives of patients in dire need of relief around the world.

Alivora's Values

To give our best in every area of operation, so that our patients make informed decisions about their health and improve the quality of their lives.

Committed To Making A Difference

Alivora Therapeutics is a bio-pharmaceutical company that is developing a pioneering cannabis medication (a prescribed pharmaceutical) with the ultimate goal of producing a Food and Drug Administration (FDA)-approved drug. MMJ to date has developed a patent-pending compound for symptomatic treatment of Multiple Sclerosis (MS), Huntington’s Disease and several other conditions. The company has initiated an FDA approval process for the MS indication that will shortly be followed by an approval process for Huntington’s Disease which the FDA has awarded an Orphan Designation.

What Makes Us Different

Alivora is one of the first companies

Alivora is leveraging the “Orphan Drug”- lowest risk cannabis business model and the most expedient way to FDA approved HD and MS and future medicines.

Has complete pharma-grade fully integrated supply chain-high-tech manufacturing capable of producing botanical controlled medicine and accommodate high demand.

Has patent-pending formulations, outcomes-centric continuous care business concept with enabling technology and R&D.

First-class expert team in big-pharma, science, medicine, law and technology.

In support of the Alivora Therapeutics’s Comprehensive Continuous Care business model, Alivora will provide a one of a kind end-to-end medical condition management solution.

Alivora Therapeutics is strategically positioned through it’s R&D capabilities, technologies, key partnerships and synergic business lines to become a market leader.

Our Product

Alivora Therapeutics has developed a pharmaceutical-cannabinoid formulation in a soft-gelatin early release capsule dose form for the treatment of symptoms associated with multiple neurological diseases: spasticity(muscle stiffness) associated with progressive Multiple Sclerosis, and Huntington’s Disease chorea(involuntary movements).

What we offer

Alivora Therapeutics offers investors a “big pharma” return at a fraction of costs and risks typical of such ventures.

Complete legal certainty, unlike any other cannabis business in the U.S.
Known safety and efficacy of cannabis for the proposed indications.
World-class, highly experienced team and key partnerships.
Strong barriers of entry for competition.
Extraordinary high profitability and investor returns.

Our Expertise

The Corporate Governance Code

The Directors of MMJ recognize the importance of the highest standards as it relates to corporate governance.

The Board of Directors

The Alivora Therapeutics Board of Directors which is majority-independent currently comprises two Executive and three independent non-executive Directors.

The Board of Directors has overall responsibility for the Group. Its aim is to represent the interests of the Group’s shareholders and to provide leadership and control in order to ensure the growth and development of a successful business.

All Directors are able to take independent advice in furtherance of their duties if necessary.

The Board is responsible to shareholders for the proper management of the Group, and Board meetings are held several times a year to set the overall direction and strategy of the Group, to review financial and operating performance and to advise on senior management appointments. Financial policy and budgets, including capital expenditure, are approved and monitored by the Board. All key strategic decisions are subject to Board approval. The Company Secretary is responsible for ensuring that Board procedures are followed and that applicable rules and regulations are complied with.

The Board attaches great importance to effective communication with shareholders and encourages dialogue with both its institutional and private investors and responds promptly to all questions received verbally or in writing. Regular communication is maintained with all shareholders through Company announcements. Directors regularly attend meetings with analysts and institutional shareholders throughout the year. With private shareholders this is not always practical. The Board has therefore sought to use the Company’s Annual General Meeting as the opportunity to meet private shareholders, after which the Board gives a presentation on the activities of the Group and there is also an opportunity to ask questions of Directors on a formal and informal basis. All shareholders have at least 21 days’ notice of the Annual General Meeting.

In addition the Company operates this website as an important investor communications tool. This website contains further details of the Group and its activities, details of regulatory announcements and Company announcements, Annual and Interim Reports, and details of the Company’s share price, share trading activity and graphs.

Maintenance of a Sound System of Internal Control

The Directors have overall responsibility for ensuring that the Group maintains a system of internal control to provide them with reasonable assurance that the assets of the Group are safeguarded and that the shareholders’ investments are protected. The system includes internal controls covering financial, operational and compliance areas, and risk management. There are limitations in any system of internal control, which can provide reasonable but not absolute assurance with respect to the preparation of financial information, the safeguarding of assets and the possibility of material misstatement or loss.

The Board has considered and reviewed the system of internal controls in place in accordance with the Turnbull Report. An assessment of the major risk areas for the business and methods used to monitor and control them was also undertaken. In addition to financial risk, the review covered operational, commercial, environmental, regulatory and research and development risks. The risk review is an ongoing process with regular review by the Board at least annually.

The key procedures designed to provide an effective system of internal control that have operated throughout the year and up to the date of the sign-off of this report are described below.

Control Environment

There is an organizational structure with clearly defined lines of responsibility and delegation of accountability and authority.